Loading...
XHKG1513
Market cap4.25bUSD
Dec 23, Last price  
26.85HKD
1D
0.37%
1Q
3.67%
Jan 2017
29.96%
Name

Livzon Pharmaceutical Group Inc

Chart & Performance

D1W1MN
XHKG:1513 chart
P/E
10.62
P/S
1.67
EPS
2.37
Div Yield, %
6.73%
Shrs. gr., 5y
-0.05%
Rev. gr., 5y
7.00%
Revenues
12.43b
-1.58%
1,554,787,6001,626,145,8771,510,051,3571,748,108,3972,058,640,5732,595,847,0522,726,718,8953,162,915,2943,943,525,3054,618,680,0405,544,233,7776,620,516,5367,651,775,2858,530,968,5968,860,655,6709,384,695,83510,520,409,84212,063,863,27212,629,579,04712,430,038,325
Net income
1.95b
+2.32%
124,058,279107,891,938139,149,523508,451,06052,073,163481,578,249418,180,831359,369,880441,671,519487,502,351515,978,431622,641,033784,353,6074,428,684,5641,082,174,9051,302,875,4401,714,910,3901,775,683,2511,909,407,6871,953,650,833
CFO
3.39b
+22.42%
181,461,509161,070,286226,461,050248,553,495345,176,898494,877,099633,296,307708,201,336593,964,664439,986,525717,393,893927,788,4601,279,215,0371,315,865,4671,267,621,1811,767,162,8822,160,760,6061,902,328,1392,772,671,2953,394,202,141
Dividend
Jul 08, 20241.48203 HKD/sh
Earnings
Mar 26, 2025

Profile

Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.
URL
https://www.livzon.com.cn/
IPO date
Oct 28, 1993
Employees
8,649
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
12,430,038
-1.58%
12,629,579
4.69%
12,063,863
14.67%
Cost of revenue
9,544,891
10,432,055
9,524,515
Unusual Expense (Income)
NOPBT
2,885,147
2,197,524
2,539,349
NOPBT Margin
23.21%
17.40%
21.05%
Operating Taxes
485,066
375,010
293,588
Tax Rate
16.81%
17.07%
11.56%
NOPAT
2,400,082
1,822,513
2,245,761
Net income
1,953,651
2.32%
1,909,408
7.53%
1,775,683
3.54%
Dividends
(1,487,558)
(1,215,354)
(1,168,522)
Dividend yield
4.57%
4.00%
3.11%
Proceeds from repurchase of equity
(369,704)
(1)
BB yield
1.13%
0.00%
Debt
Debt current
1,860,010
1,632,681
2,052,332
Long-term debt
1,630,835
1,997,660
647,329
Deferred revenue
269,370
273,209
258,883
Other long-term liabilities
90,000
84,000
78,000
Net debt
(9,586,775)
(8,519,222)
(8,141,595)
Cash flow
Cash from operating activities
3,394,202
2,772,671
1,902,328
CAPEX
(820,452)
Cash from investing activities
(777,112)
Cash from financing activities
(1,733,411)
FCF
2,961,943
1,236,863
1,366,962
Balance
Cash
11,407,516
10,519,442
9,329,147
Long term investments
1,670,104
1,630,121
1,512,109
Excess cash
12,456,118
11,518,084
10,238,063
Stockholders' equity
13,736,755
13,569,858
12,944,220
Invested Capital
6,151,769
7,138,593
6,943,846
ROIC
36.12%
25.88%
36.81%
ROCE
15.33%
11.66%
14.65%
EV
Common stock shares outstanding
930,609
935,892
934,461
Price
35.01
7.79%
32.48
-19.22%
40.21
-0.72%
Market cap
32,580,615
7.18%
30,397,764
-19.10%
37,574,666
-1.15%
EV
23,718,048
22,938,773
30,740,332
EBITDA
3,725,471
2,849,848
2,984,620
EV/EBITDA
6.37
8.05
10.30
Interest
102,086
97,546
83,997
Interest/NOPBT
3.54%
4.44%
3.31%